Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Qiagen ( (QGEN) ) has issued an update.
QIAGEN N.V. announced a synthetic share repurchase, consolidating every 36 issued shares into 35 shares, as approved in June 2024. This transaction impacted Lawrence Rosen’s holdings, reducing his shares by 415 to a total of 14,495 common shares. The move is part of a broader financial strategy and reflects on QIAGEN’s efforts to optimize its capital structure, potentially affecting shareholder value and market perception.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its expertise in developing products that enable the analysis of the building blocks of life (DNA, RNA, and proteins), which are used in laboratories worldwide.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.
